Improved outcome with novel device for low-pressure PTCA in de novo and in-stent lesions

Atorvastatin combining with probucol: a new way to reduce serum uric acid level during perioperative period of interventional procedure

Uric acid has ever been considered as one of contrast induced acute kidney injury's risk factors. Atorvastatin and probucol can both improve contrast induced acute kidney injury separately. This prospective study is to assess their effect on reducing serum uric acid level and contrast induced acute kidney injury during perioperative period of interventional procedure. On the basis of different doses of atorvastatin and probucol, 208 cases admitted for coronary angiography or percutaneous coronary intervention were randomly classified into standard combined group (S-C group), intensive combined group (I-C group), and intensive atorvastatin group (I-A group). Patients' blood urea nitrogen, serum creatinine, and serum uric acid were measured and estimated glomerular filtration rate was evaluated 24 hours before and after the procedure. After procedure, blood urea nitrogen in all the three groups decreased; Scr of S-C group and I-A group increased significantly, while estimated glomerular filtration decreased in the S-C group (P < 0.05); serum uric acid in S-C group and I-C group decreased significantly (P < 0.05). Combination treatment of atorvastatin and probucol before intervention could reduce perioperative serum uric acid level; meanwhile, the intensive combined treatment can improve the contrast induced acute kidney injury. The result was the same for hypertensive patients.

Hazards of contrast-induced acute kidney injury in elderly women

Evaluation of: Sidhu RB, Brown JR, Robb JF et al.: Interaction of gender and age on post cardiac catheterization contrast-induced acute kidney injury. Am. J. Cardiol. 102(11), 1482–1486 (2008). A total of 13,127 consecutive patients undergoing coronary angiography with complete data were grouped by age and gender into four age categories (<50, 51–64, 65–79 and >80 years). Rates of postcatheterization contrast-induced acute kidney injury were higher for women compared with men in the 65–79 years (14.5 vs 11.0%; p < 0.001) and over 80 years (18.7 vs 15.1%; p = 0.048) age groups.

Is chronic kidney disease associated with coronary artery stenosis or calcification as assessed by multi-detector row computed tomography?

BACKGROUND

The coronary artery calcification (CAC) score as determined by multi-detector row computed tomography (MDCT) is known to predict coronary artery disease (CAD). Chronic kidney disease (CKD) is also known to be a risk factor for CAD. Little is known about the relationship between CKD and the severity of coronary artery stenosis or CAC as determined by MDCT, a non-invasive method for screening.

METHODS AND RESULTS

The subjects included 313 consecutive patients who underwent MDCT angiography. We quantified the number of significantly stenosed vessels in coronary vessel disease (VD) and CAC score using MDCT and measured body mass index (BMI), waist circumference and blood pressure. We also analyzed plasma levels of lipid profile, hemoglobin A1c, uric acid, and creatinine. Furthermore, we calculated the estimated glomerular filtration rate (eGFR), and defined CKD as GFR <60 mL/min/1.73 m(2). eGFR levels in the 3-VD group were significantly lower than those in patients without stenosed vessels. In the two classifications that were based on the CAC score [low (L, 0-444) and high (H, >or=445)] in our previous report, the H group was significantly associated with age, number of VD, incidence of hypertension and CKD. Multivariate logistic regression analysis revealed that the high CAC score group was significantly correlated with age (p=0.0023), CKD (p=0.0109) and number of VD (p=0.0470).

CONCLUSION

CKD may contribute to the severity of CAD associated with the progression of CAC. Therefore, therapeutic intervention for CKD, in addition to the improvement of conventional risk factors, is needed to prevent CAD when MDCT is performed.

Coronary interventional devices: balloon, atherectomy, thrombectomy and distal protection devices

With increased operator experience and improved device technology, there has been a constant growth in the number of complex lesions (ie, thrombotic lesions, diffuse lesions,calcified lesions, nondilatable rigid lesions, ostial lesions, bifurcations, and chronic total occlusions) attempted by interventionalists with the use of drug-eluting stents. Although coronary stent implantation remains the mainstay and ultimate step for the treatment of most coronary lesions, adjunctive devices may be essential for lesion preparation in some cases (5%-10%) to allow stent deployment and expansion and prevent distal embolization. Thrombectomy and distal protection devices have shown to be effective in the interventions of saphenous vein graft lesions, although their use remains unproven in acute myocardial infarctions.

Implications of the "watermelon seeding" phenomenon during coronary interventions for in-stent restenosis

The occurrence of balloon slippage ("watermelon seeding"; WMS) during treatment of patients with in-stent restenosis (ISR) has been described, but predisposing factors and the potential implications of this phenomenon remain unknown. In the Restenosis Intrastent: Balloon Angioplasty vs. Elective Stenting (RIBS) randomized study, 450 patients with ISR were included. Of these, 42 patients (9%) presented WMS during the procedure. WMS was detected in 26 patients (12%) in the balloon arm and 16 (7%) in the stent arm (P=0.11). In the stent arm, WMS was only noticed during balloon predilation, never during stent implantation. As compared with 408 patients without WMS, patients with WMS had more severe (TIMI flow 1; 21% vs. 8%; P=0.01) and diffuse (length>15 mm: 45% vs. 28%; P=0.02) ISR lesions. Patients with WMS required more balloon inflations, longer total inflation time, had more frequent crossover to stenting or ended the procedure with residual dissections, and eventually obtained poorer acute results (minimal lumen diameter, 2.35+/-0.5 vs. 2.53+/-0.5 mm; P=0.03). In addition, at 6-month follow-up, patients with WMS had a smaller minimal lumen diameter (1.26+/-0.7 vs. 1.61+/-0.7 mm; P=0.007) and a higher restenosis rate (56% vs. 37%; P=0.017). On logistic regression analysis, the WMS phenomenon emerged as an independent predictor of recurrent restenosis (adjusted RR=2.1; 95% CI=1.1-4.1; P=0.04). The WMS phenomenon may complicate treatment of patients with ISR. Long and severe lesions appear to predispose to this technical problem that never occurs during stent deployment. In patients with ISR, WMS is associated with cumbersome procedures and poorer acute and long-term angiographic results.

N-acetylcysteine for prevention of radiographic contrast material-induced nephropathy: is the intravenous route best?

Use of oral N-acetylcysteine for preventing radiographic contrast material-induced nephropathy (RCIN) has become widespread, despite conflicting results from clinical trials and meta-analyses. The variability in study results may reflect differences in baseline risks in study patients, hydration regimens, choice of contrast agent, definition of RCIN, and the oral dosage formulation of N-acetylcysteine used. Injectable N-acetylcysteine recently has become available in the United States. Although oral N-acetylcysteine regimens are typically administered during a 48-hour period, more rapid intravenous administration could offer an important advantage for urgent procedures such as coronary angiography. However, the three published studies in which intravenous N-acetylcysteine protocols were used have produced divergent results, likely because of substantially different dosage regimens. With few intravenous studies available, clinicians may look to more broadly studied oral regimens to estimate equivalent intravenous dosages. In the oral studies, however, a wide range of formulations were used, and the bioavailability of each product was uncertain. In addition, the intravenous route circumvents first-pass metabolism, resulting in less glutathione production, perhaps compromising the antioxidant effects of N-acetylcysteine administration. Overall, little evidence exists that any studied N-acetylcysteine protocol improves clinical outcomes in terms of reducing length of hospital stay, need for dialysis, or mortality. Furthermore, N-acetylcysteine may directly affect serum creatinine level, which all clinical trials to date have used as a primary outcome measure. If oral or intravenous N-acetylcysteine is used with the intention of preventing RCIN, more established preventive measures should not be overlooked, including adequate hydration with isotonic saline, avoidance of potentially nephrotoxic drugs, and use of iso-osmolar radiographic contrast media.

Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction

BACKGROUND

The presence of coexisting conditions has a substantial effect on the outcome of acute myocardial infarction. Renal failure is associated with one of the highest risks, but the influence of milder degrees of renal impairment is less well defined.

METHODS

As part of the Valsartan in Acute Myocardial Infarction Trial (VALIANT), we identified 14,527 patients with acute myocardial infarction complicated by clinical or radiologic signs of heart failure, left ventricular dysfunction, or both, and a documented serum creatinine measurement. Patients were randomly assigned to receive captopril, valsartan, or both. The glomerular filtration rate (GFR) was estimated by means of the four-component Modification of Diet in Renal Disease equation, and the patients were grouped according to their estimated GFR. We used a 70-candidate variable model to adjust and compare overall mortality and composite cardiovascular events among four GFR groups.

RESULTS

The distribution of estimated GFR was wide and normally shaped, with a mean (+/-SD) value of 70+/-21 ml per minute per 1.73 m2 of body-surface area. The prevalence of coexisting risk factors, prior cardiovascular disease, and a Killip class of more than I was greatest among patients with a reduced estimated GFR (less than 45.0 ml per minute per 1.73 m2), and the use of aspirin, beta-blockers, statins, or coronary-revascularization procedures was lowest in this group. The risk of death or the composite end point of death from cardiovascular causes, reinfarction, congestive heart failure, stroke, or resuscitation after cardiac arrest increased with declining estimated GFRs. Although the rate of renal events increased with declining estimated GFRs, the adverse outcomes were predominantly cardiovascular. Below 81.0 ml per minute per 1.73 m2, each reduction of the estimated GFR by 10 units was associated with a hazard ratio for death and nonfatal cardiovascular outcomes of 1.10 (95 percent confidence interval, 1.08 to 1.12), which was independent of the treatment assignment.

CONCLUSIONS

Even mild renal disease, as assessed by the estimated GFR, should be considered a major risk factor for cardiovascular complications after a myocardial infarction.

Focused force angioplasty: theory and application

Focused force angioplasty is a technique in which the forces resulting from inflating an angioplasty balloon in a stenosis are concentrated and focused at one or more locations within the stenosis. While the technique has been shown to be useful in resolving resistant stenoses, its real value may be in minimizing the vascular trauma associated with balloon angioplasty and subsequently improving the outcome.